This trial is active, not recruiting.

Condition coronary artery disease
Treatment pexelizumab in conjunction with cabg
Phase phase 3
Sponsor Alexion Pharmaceuticals
Collaborator Procter and Gamble
Start date July 2004
End date October 2005
Trial size 4000 participants
Trial identifier NCT00088179, 2003141


During a heart bypass procedure, a substance called "complement" is activated by the body. This "complement activation" causes an inflammatory response that can lead to side affects such as chest pain, heart attacks, stroke, heart failure, or death. The purpose of this study is to find out if the study drug (pexelizumab), that blocks "complement activation," can reduce such side effects and be given safely to patients requiring the bypass procedure with the use of the heart-lung machine.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Allocation randomized
Intervention model parallel assignment
Primary purpose treatment
Masking double blind (masked roles unspecified)

Primary Outcomes

Reduction in mortality.
time frame:
Reduction in MI incidence.
time frame:

Eligibility Criteria

All participants at least 18 years old.

Inclusion Criteria: - be at least 18 years of age; - have 2 or more of the following risk factors: • diabetes mellitus; • repeat CABG; • the need for urgent intervention, defined according to the ACC/AHA guidelines as being patients who are required to stay in the hospital due to medical factors, but may be scheduled and operated on within a normal scheduling routine, excluding patients who have had an MI within 48 hours of CABG; • female; • history of a neurologic event (cerebrovascular accident, transient ischemic attack or carotid endarterectomy); • history of congestive heart failure (NYHA CHF Class III or IV); • history of 2 MIs, or an MI that occurred greater than 48 hours but less than 4 weeks prior to CABG; - provide Informed Consent. Exclusion Criteria: - requires salvage intervention as defined by the ACC/AHA guidelines 10 as being ongoing cardiopulmonary resuscitation on the way to the operating room; - has current cardiogenic shock, acute left ventricular rupture, acute septal rupture or acute papillary muscle rupture; - has any active bacterial or other infection which is clinically significant, in the opinion of the Investigator (e.g. evaluate the evidence based on WBC, temperature, cultures etc. as appropriate for the patient); - has a known or suspected hereditary complement deficiency; - has participated in any other investigational drug study or was exposed to an investigational agent or device within 30 days of randomization; - is receiving, or is planning to receive, any other investigational drug or device, or will participate in any other research study within 30 days of randomization; - is pregnant or breast-feeding.

Additional Information

Official title A Multicenter, Randomized, Double-Blind, Parallel-group, Placebo-Controlled Study of Pexelizumab in Patients Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass (PRIMO-CABG II)
Trial information was received from ClinicalTrials.gov and was last updated in February 2017.
Information provided to ClinicalTrials.gov by Alexion Pharmaceuticals.